AU2017254754B2 - PEGylated bioactive peptides and uses thereof - Google Patents

PEGylated bioactive peptides and uses thereof Download PDF

Info

Publication number
AU2017254754B2
AU2017254754B2 AU2017254754A AU2017254754A AU2017254754B2 AU 2017254754 B2 AU2017254754 B2 AU 2017254754B2 AU 2017254754 A AU2017254754 A AU 2017254754A AU 2017254754 A AU2017254754 A AU 2017254754A AU 2017254754 B2 AU2017254754 B2 AU 2017254754B2
Authority
AU
Australia
Prior art keywords
peg
xaa
ala
salt
ghrh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017254754A
Other languages
English (en)
Other versions
AU2017254754A1 (en
Inventor
Krishna G. Peri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffon Pharmaceuticals International SA
Original Assignee
Griffon Pharmaceuticals Int SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffon Pharmaceuticals Int SA filed Critical Griffon Pharmaceuticals Int SA
Publication of AU2017254754A1 publication Critical patent/AU2017254754A1/en
Assigned to GRIFFON PHARMACEUTICALS INTERNATIONAL SA reassignment GRIFFON PHARMACEUTICALS INTERNATIONAL SA Request for Assignment Assignors: GRIFFON PHARMACEUTICALS INC.
Application granted granted Critical
Publication of AU2017254754B2 publication Critical patent/AU2017254754B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2017254754A 2016-04-19 2017-04-18 PEGylated bioactive peptides and uses thereof Ceased AU2017254754B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
US62/324,600 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (2)

Publication Number Publication Date
AU2017254754A1 AU2017254754A1 (en) 2018-11-01
AU2017254754B2 true AU2017254754B2 (en) 2021-02-04

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017254754A Ceased AU2017254754B2 (en) 2016-04-19 2017-04-18 PEGylated bioactive peptides and uses thereof

Country Status (18)

Country Link
US (2) US9988428B2 (enExample)
EP (1) EP3445778B1 (enExample)
JP (1) JP7134093B2 (enExample)
KR (1) KR102520348B1 (enExample)
CN (1) CN109153712B (enExample)
AU (1) AU2017254754B2 (enExample)
BR (1) BR112018070929A2 (enExample)
CA (1) CA3021231A1 (enExample)
DK (1) DK3445778T3 (enExample)
ES (1) ES2824781T3 (enExample)
HU (1) HUE052802T2 (enExample)
IL (1) IL262356B2 (enExample)
MX (1) MX2018012716A (enExample)
PL (1) PL3445778T3 (enExample)
PT (1) PT3445778T (enExample)
RU (1) RU2748576C2 (enExample)
SG (1) SG11201808880PA (enExample)
WO (1) WO2017181277A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110469PA (en) 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
CN116194344A (zh) 2020-10-09 2023-05-30 奥托立夫开发公司 安全气囊装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027897A1 (en) * 1997-12-03 1999-06-10 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
EP0542937A1 (en) 1991-04-09 1993-05-26 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
JPH11503454A (ja) 1995-04-14 1999-03-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 成長ホルモン放出因子の類似体
ES2163020T3 (es) 1995-05-26 2002-01-16 Theratechnologies Inc Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica.
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
ATE309358T1 (de) 1999-07-26 2005-11-15 Baylor College Medicine Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein
AU9558901A (en) 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
MXPA05002991A (es) 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
WO2007025988A2 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
JP2011511778A (ja) * 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
ES2732205T3 (es) 2008-06-12 2019-11-21 Ipsen Bioinnovation Ltd Proteínas de fusión para uso en el tratamiento del cáncer
CA2745499A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
MX2013012259A (es) * 2011-04-21 2013-11-22 Theratechnologies Inc Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
WO2017023933A2 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027897A1 (en) * 1997-12-03 1999-06-10 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A MUNAFO ET AL, "Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects", EUROPEAN JOURNAL OF ENDOCRINOLOGY, GB, (2005-08-01), vol. 153, no. 2, pages 249 - 256 *
CAMPBELL et al., "Pegylated peptides V: Carboxy-terminal PEGylated analogs of growth hormone-releasing (GRF) display enhanced duration of biological activity in vivo", J. Peptide Res., (1997-06), vol. 49, no. 6, pages 527 - 537 *
D'ANTONIO et al., "Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs", Growth Hormone & IGF Research, (2004), vol. 14, pages 226 - 234 *
ESPOSITO et al., "PEGylation of growth hormone-releasing hormone (GRF) analogues", Advanced Drug Delivery Reviews, (2003), vol. 55, no. 10, pages 1279 - 1291 *
FELIX et al., "Pegylated peptides IV: Enhanced biological activity of site-directed pegylated GRF analogs", Int. J. Peptide Protein Res., (1995-09), vol. 46, pages 253 - 264 *
YOUN et al., "Site-specific PEGylation for High-Yield Preparation of Lys21-Amine PEGylated Growth Hormone-Releasing Factor (GRF) (1-29) . . .", Bioconjugate Chem., (2007-03), vol. 18, pages 500 - 506 *

Also Published As

Publication number Publication date
RU2018140501A3 (enExample) 2020-09-08
CN109153712A (zh) 2019-01-04
HUE052802T2 (hu) 2021-05-28
US20170296628A1 (en) 2017-10-19
JP7134093B2 (ja) 2022-09-09
CA3021231A1 (en) 2017-10-26
EP3445778A4 (en) 2019-05-01
US10918730B2 (en) 2021-02-16
DK3445778T3 (da) 2020-10-12
CN109153712B (zh) 2022-09-16
EP3445778B1 (en) 2020-07-15
KR102520348B1 (ko) 2023-04-10
WO2017181277A1 (en) 2017-10-26
RU2018140501A (ru) 2020-05-19
MX2018012716A (es) 2019-02-11
IL262356B2 (en) 2023-06-01
US9988428B2 (en) 2018-06-05
US20190209699A1 (en) 2019-07-11
PT3445778T (pt) 2020-10-15
IL262356A (en) 2018-11-29
EP3445778A1 (en) 2019-02-27
AU2017254754A1 (en) 2018-11-01
ES2824781T3 (es) 2021-05-13
RU2748576C2 (ru) 2021-05-27
SG11201808880PA (en) 2018-11-29
BR112018070929A2 (pt) 2019-02-26
KR20180135016A (ko) 2018-12-19
JP2019516675A (ja) 2019-06-20
PL3445778T3 (pl) 2021-02-22

Similar Documents

Publication Publication Date Title
AU2008205229B2 (en) Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
CN100506844C (zh) 新的肽
US11572399B2 (en) Long-acting GIP peptide analogues
CA2859675C (en) Novel gh-rh analogs with potent agonistic effects
AU2017254754B2 (en) PEGylated bioactive peptides and uses thereof
US8361964B2 (en) Growth hormone releasing factor (GRF) analogs and uses thereof
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
JP2026505071A (ja) Ｇｉｐ／ｇｌｐ１／ｇｃｇ三受容体アゴニスト及びそれらの使用
HK1121688A1 (en) Glucagon analogs exhibiting physiological solubility and stability
HK1121688B (en) Glucagon analogs exhibiting physiological solubility and stability

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PERI, KRISHNA G.

PC1 Assignment before grant (sect. 113)

Owner name: GRIFFON PHARMACEUTICALS INTERNATIONAL SA

Free format text: FORMER APPLICANT(S): GRIFFON PHARMACEUTICALS INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired